Veterinary Oncology Is Booming: What It Means for Your Dog

Reviewed by Dr. Jamshed Bilal, DVM

Cancer care for pets is entering a new era, and the numbers behind it are striking. According to a report from Global Market Insights, Inc., the global veterinary oncology market was valued at USD 2 billion in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 10.3%, reaching USD 5.4 billion by 2035. For dog owners, this is not just an abstract industry statistic — it reflects a real shift in what is now possible when a dog is diagnosed with cancer, how early that diagnosis can happen, and how much treatment is likely to cost.

Why Cancer Care for Dogs Is Expanding So Quickly

Several trends are converging to drive this growth. Dog ownership continues to rise globally, and owners are increasingly willing to invest in comprehensive healthcare rather than basic maintenance alone. That shift in spending is being matched by a steadily expanding pipeline of veterinary oncology drugs and diagnostic tools reaching the market.

At the same time, dogs are living longer thanks to improvements in preventive care — better vaccination protocols, parasite control, and nutrition — which naturally increases the incidence of age-related cancers and expands the population of dogs who need treatment. Attitudes toward treatment itself are also changing: more owners are choosing active cancer therapies such as chemotherapy or targeted treatment instead of settling for purely supportive or palliative care when a diagnosis arrives.

Technology is playing an equally important role. Advances in diagnostic imaging — CT, MRI, and digital radiography — combined with molecular testing and minimally invasive biopsy techniques are enabling earlier cancer detection and more precise treatment planning. As the cost of this equipment continues to decline, general veterinary practices, not just specialised referral centres, are increasingly able to offer oncology screening. That is widening access for everyday dog owners, not just those near a large veterinary hospital.

Diagnostics Are Leading the Growth

Among the different segments of the veterinary oncology market, diagnostics held the largest share in 2025, accounting for 43.9% of the market, and is expected to grow at a CAGR of 10.4% through 2035. This dominance is driven by the growing use of advanced imaging and laboratory-based diagnostic tools across both specialty hospitals and general veterinary practices that have upgraded their capabilities.

Imaging technologies remain the single biggest contributor to this growth, with CT, MRI, ultrasound, and digital radiography systems used extensively for tumour detection, staging, and treatment planning. In parallel, minimally invasive procedures such as ultrasound-guided sampling are improving diagnostic accuracy while reducing risk to the dog, making biopsy a less daunting step for owners to agree to.

For an owner, the practical takeaway is this: a suspicious lump or symptom no longer necessarily means a long wait for a referral appointment at a distant specialty hospital. More general practice vets now have direct access to the imaging tools needed to investigate promptly.

Lymphoma: The Most Common Cancer Diagnosis in Dogs

By cancer type, lymphoma represented the largest share of the veterinary oncology market in 2025 at 27.4%, with a projected CAGR of 10.8% through 2035. Canine lymphoma is by far the most frequently diagnosed cancer in dogs, and it is generally categorised into four types: multicentric, alimentary, mediastinal, and extranodal. Of these, aggressive multicentric lymphoma — which affects the lymph nodes and often first appears as painless swelling under the jaw, in front of the shoulders, or behind the knees — is the most commonly observed in clinical practice.

Treatment protocols for canine lymphoma are largely modelled on multi-agent chemotherapy regimens adapted from human oncology, but the doses and drug combinations are specifically calibrated for dogs. These protocols have proven effective, continuing to deliver strong remission rates and meaningfully extended survival times. Just as importantly, dogs generally tolerate chemotherapy far better than human patients do — severe side effects are uncommon, and most dogs maintain a good quality of life throughout a course of treatment, since veterinary oncologists prioritise comfort alongside remission.

Where This Care Is Most Available Right Now

Geographically, North America led the global veterinary oncology market with a 49.8% share in 2025, and the region is expected to maintain a CAGR of 10.1% through 2035. This leadership stems from a highly developed veterinary healthcare ecosystem, a strong supply of specialist veterinary oncologists, and a regulatory environment that actively supports approval of new veterinary drugs.

The United States in particular sits at the centre of this regional dominance, with leading academic institutions and referral hospitals continuing to drive clinical research and treatment innovation for companion animals. For dog owners in North America, this generally translates into a shorter path to a board-certified veterinary oncologist if a general practice vet recommends a referral.

Who Is Building This Industry

The veterinary oncology space includes a mix of established animal health companies and specialised oncology technology providers, including Zoetis, Boehringer Ingelheim, Elanco Animal Health, Merck Animal Health, IDEXX Laboratories, Siemens Healthineers (through its Varian Medical Systems division), Accuray, Elekta, PetCure Oncology, Virbac, and Dechra Pharmaceuticals, among others. These companies span the full spectrum of the market — from drug development and diagnostic imaging equipment to dedicated cancer treatment centres for pets — reflecting how the field has matured into a genuinely multidisciplinary specialty.

What This Means for You and Your Dog

A growing market is good news for dog owners in three concrete ways. First, earlier detection: as imaging and screening tools spread beyond specialist hospitals, more vets will be equipped to investigate a suspicious symptom promptly rather than referring and waiting. Second, more treatment options: an expanding pipeline of oncology drugs and technologies means fewer cancer diagnoses end with "there's nothing more we can do." Third, better-informed decisions: as oncology becomes a more visible and mainstream part of veterinary medicine, owners get clearer information about prognosis, treatment costs, and realistic expectations before committing to a course of care.

The flip side is cost. Advanced diagnostics and specialist treatment are not cheap, and a full course of chemotherapy or radiation for a dog can run into several thousand dollars. This is one of the strongest arguments for taking out pet insurance while a dog is young and healthy — cancer is exactly the kind of diagnosis that most exposes owners without coverage to a difficult financial decision at an already stressful time.

The single most useful thing an owner can do is not wait. Annual wellness exams — twice yearly once a dog reaches senior age — combined with prompt attention to new lumps, unexplained weight loss, lethargy, or appetite changes gives a dog the best possible shot at catching cancer while it is still highly treatable. Ask your vet directly whether any finding warrants further diagnostic workup; with the tools now available, that question is easier to answer than it has ever been.

Frequently Asked Questions

Why is veterinary oncology growing so fast?

Pets are living longer due to better preventive care, which increases age-related cancer cases; more owners are choosing active treatment over palliative care; and diagnostic technology has become affordable enough for general practices to offer, not just specialist referral hospitals.

What is the most common cancer in dogs?

Lymphoma, representing roughly a quarter of veterinary oncology cases. It has four main types — multicentric, alimentary, mediastinal, and extranodal — with multicentric lymphoma being the most commonly diagnosed in clinical practice.

Is chemotherapy for dogs the same as for humans?

Protocols are adapted from human oncology but tailored specifically to dogs. Dogs generally tolerate chemotherapy better than humans, maintaining good quality of life throughout treatment, since veterinary protocols prioritise comfort alongside remission.

Will pet cancer treatment get more accessible?

Yes — as diagnostic equipment becomes cheaper, more general practices are adding imaging and screening capability, which is expected to widen access to earlier diagnosis, the biggest factor in successful outcomes.

What can dog owners do given rising cancer rates?

Prioritise regular wellness exams, learn early warning signs like unexplained lumps or weight loss, ask your vet about further workup promptly, and consider pet insurance while your dog is young and healthy.

For more on keeping your dog healthy at every life stage, see the dog health warning signs guide and the senior dog care guide. For a full overview of dog care, visit the complete dog care guide.

---

Source: Veterinary Oncology Market Report, Global Market Insights, Inc.

Disclaimer: This article is for educational purposes only. Always consult a licensed veterinarian for your pet's health and medical needs.